ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P. Tarantino(Harvard University), G. Curigliano(University of Milan), Stuart J. Schnitt(Brigham and Women's Hospital), Federico Rojo(Hospital Universitario Fundación Jiménez Díaz), George Pentheroudakis(Hellenic Cooperative Oncology Group), H.J. Burstein(Harvard University), P. Schmid(Queen Mary University of London), Shanu Modi(Memorial Sloan Kettering Cancer Center), Dario Trapani(Harvard University), Anna Batistatou(University of Ioannina), Roberto Salgado(Peter MacCallum Cancer Centre), A. Bardia(Harvard University), Javier Cortés(Villa Maria Hospital), William Jacot(Inserm), C. Denkert(Philipps University of Marburg), Michael F. Press(USC Norris Comprehensive Cancer Center), Frédérique Penault‐Llorca(Inserm), Giulia Viale(Istituti di Ricovero e Cura a Carattere Scientifico), A. Vincent-Salomon(Université Paris Sciences et Lettres), Elena Provenzano(University of Cambridge), A.C. Wolff(Sidney Kimmel Comprehensive Cancer Center), Giancarlo Pruneri(University of Milan), S.M. Tolaney(Harvard University), Jorge S. Reis‐Filho(AstraZeneca (France)), Alizée Lebeau(University of Liège), M.F. Mosele(Institut Gustave Roussy), L.A. Carey(University of North Carolina at Chapel Hill), Xin Hu(Fudan University Shanghai Cancer Center), S. Loibl(German Breast group), V. Diéras(Centre Eugène Marquis), A. Koutras(General University Hospital of Patras), Fabrice André(Inserm)
Cited by 298
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k